Medtronic demonstrated robust performance in its latest quarter, reporting an 11% year-over-year revenue growth, driven significantly by innovation in cardiovascular and neurological segments.

• The Cardiovascular portfolio achieved 11% revenue growth, with CAS growing a staggering 80% year-over-year.
• The Hugo robot received FDA clearance for urologic procedures, marking a significant step in its U.S. market entry with early installations at hospitals like Cleveland Clinic.
• The introduction of Altaviva for urge urinary incontinence has garnered strong initial interest, reflecting effective direct-to-consumer marketing efforts.
• Stealth AXiS surgical system has received FDA clearance, enhancing Medtronic's capabilities in spinal procedures and expanding their leadership in surgical navigation.
• Continued focus on innovation is expected to drive sustained growth across high-need categories, with new product launches in the pipeline.